News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Opinion|Videos|August 6, 2024

ITB Pump for Spasticity: Surveillance Registry Findings

Author(s)Khashayar Dashtipour, MD, PhD, Francois Bethoux, MD, Jennifer Smith, PA

Experts on spasticity discuss how patients do with ITB over the long term, highlighting replacement and discontinuation data from the Product Surveillance Registry.

Episodes in this series

Video 1 - 4 KOLs are feature in, "Definition and Pathophysiology of Spasticity"

EP. 1 Definition and Pathophysiology of Spasticity

Video 2 - 4 KOLs are feature in, "Changes in Presentation of Spasticity Over Time"

EP. 2 Changes in Presentation of Spasticity Over Time

4 KOLs are featured in this series.

EP. 3 Impact of Spasticity of Patient and Caregiver’s Quality of Life

4 KOLs are featured in this series.

EP. 4 Factors Influencing Treatment Choice in Spasticity

4 KOLs are featured in this series.

EP. 5 Treatment Options for Spasticity

4 KOLs are featured in this series.

EP. 6 Planning Spasticity Treatment Based on Patient Goals

4 KOLs are featured in this series.

EP. 7 Defining Severe Spasticity

4 KOLs are featured in this series.

EP. 8 Intrathecal Baclofen for Management of Severe Spasticity

4 KOLs are featured in this series.

EP. 9 Baclofen Pump for Treatment of Severe Spasticity

4 KOLs are featured in this series.

EP. 10 Managing Safety Concerns with ITB Pump

4 KOLs are featured in this series.

EP. 11 Ideal Candidates for ITB Pump

4 KOLs are featured in this series.

EP. 12 Long-term Data with ITB Pumps for Spasticity

A panel of 4 experts on spasticity

EP. 13 ITB Pump for Spasticity: Surveillance Registry Findings

A panel of 4 experts on spasticity

EP. 14 Practical Considerations when Using ITB Pump for Spasticity

A panel of 4 experts on spasticity

EP. 15 Potential for Use of ITB Pump Earlier in Spasticity

A panel of 4 experts on spasticity

EP. 16 Trends in Treatment of Spasticity

A panel of 4 experts on spasticity

EP. 17 Advice for Clinicians Treating Spasticity

Video content above is prompted by the following:

How well do patients with severe spasticity do with ITB over the long term?
- Discuss replacement and discontinuation data from the Product Surveillance Registry.
  - What do these results add to what we already know about ITB in this patient population?

Newsletter

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related Content

Brandy Matthews, MD

Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD

ByBrandy Matthews, MD,Isabella Ciccone, MPH

December 4th 2025

Neils Prins, MD, PhD

Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease

ByLouie Pasculli

December 4th 2025

Sid O’Bryant, PhD

Brainstorming Ways of Improving Representation Across Alzheimer Disease Clinical Research: Sid O’Bryant, PhD

BySid O’Bryant, PhD,Isabella Ciccone, MPH

December 4th 2025

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease

December 4th 2025

Kanta Horie, PhD, MEng (Credit: Washington University School of Medicine)

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease

ByIsabella Ciccone, MPH

December 4th 2025

Latest CME

Identifying and Treating CIDP in the Modern Era

Identifying and Treating CIDP in the Modern Era

Jeffrey A. Allen, MD; Karissa L. Gable, MD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy

John Brandsema, MD; Carla D. Zingariello, DO

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Abigail N. Schwaede, MD; Emmanuelle (Noelle) Tiongson, MD

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

Shamik Bhattacharyya, MD, MS, FAAN; Mirla Avila, MD; Dean Wingerchuk, MD

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

Richard Bedlack, MD, PhD

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Terry Heiman-Patterson, MD

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

PER Postgame™: Updates from ANNA in the Management of IgA Nephropathy

Gerald Bernard Appel, MD; Ellie Kelepouris, MD, FACP, FAHA

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

James F. Howard Jr, MD, FAAN

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Basil T. Darras, MD

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Katherine Ruzhansky, MD, MS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease

Newly Launched Phase POLARIS-AD Trial Tests Oral Therapy AR1001 for Early Alzheimer Disease

New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease

Autologous Stem Cell Approach Shows Promising Early Phase 1 Data in Alzheimer Disease

Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD

© 2025 MJH Life Sciences^®

All rights reserved.